A review of patient-reported outcomes used for regulatory approval of oncology medicinal products in the European Union between 2017 and 2020

INTRODUCTION: Cancer and corresponding available treatments are associated with substantial symptoms and functional limitations. In this context, collection of patient-reported outcomes (PRO) in clinical trials gained special interest and is recommended by regulatory authorities. Within clinical tri...

Descripción completa

Detalles Bibliográficos
Autores principales: Teixeira, Maria Manuel, Borges, Fábio Cardoso, Ferreira, Paula Sousa, Rocha, João, Sepodes, Bruno, Torre, Carla
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9411861/
https://www.ncbi.nlm.nih.gov/pubmed/36035431
http://dx.doi.org/10.3389/fmed.2022.968272

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9411861/
https://www.ncbi.nlm.nih.gov/pubmed/36035431
http://dx.doi.org/10.3389/fmed.2022.968272

Ejemplares similares